Matthew Caufield
Recent Articles about Aldeyra Therapeutics Inc.
Biotech Downgraded to Neutral After Second FDA CRL for Reproxalap in Dry Eye Disease 05/05/2026
H.C. Wainwright & Co. downgraded Aldeyra Therapeutics Inc. (ALDX:NASDAQ) to Neutral and slashed its price target after the company received a second FDA Complete Response Letter for its Reproxalap NDA in dry eye disease.
© 2026 Streetwise Reports. All rights reserved.
Streetwise Reports is registered with the U.S. Patent and Trademark Office.
